BridgeBio Pharma, Inc. (BBIO)

NASDAQ: BBIO · IEX Real-Time Price · USD
35.95
-1.26 (-3.39%)
At close: Feb 20, 2024, 4:00 PM
36.05
+0.10 (0.28%)
After-hours: Feb 20, 2024, 4:21 PM EST
-3.39%
Market Cap 6.25B
Revenue (ttm) 9.43M
Net Income (ttm) -612.65M
Shares Out 173.97M
EPS (ttm) -3.90
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,666,657
Open 37.00
Previous Close 37.21
Day's Range 35.14 - 37.82
52-Week Range 10.57 - 44.32
Beta 1.07
Analysts Strong Buy
Price Target 43.00 (+19.61%)
Earnings Date Mar 1, 2024

About BBIO

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 cli... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 27, 2019
Employees 578
Stock Exchange NASDAQ
Ticker Symbol BBIO
Full Company Profile

Financial Performance

In 2022, BBIO's revenue was $77.65 million, an increase of 11.38% compared to the previous year's $69.72 million. Losses were -$481.18 million, -14.46% less than in 2021.

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for BBIO stock is "Strong Buy." The 12-month stock price forecast is $43.0, which is an increase of 19.61% from the latest price.

Price Target
$43.0
(19.61% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

BridgeBio Pharma and Kyowa Kirin Announce Partnership with an Upfront Payment of $100 Million for an Exclusive License on Infigratinib in Skeletal Dysplasias in Japan

- BridgeBio grants Kyowa Kirin exclusive license to develop and commercialize infigratinib for skeletal dysplasias in Japan

13 days ago - GlobeNewsWire

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PALO ALTO, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and ...

14 days ago - GlobeNewsWire

BridgeBio Pharma Announces U.S. Food and Drug Administration (FDA) Acceptance of New Drug Application (NDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

- Accepted with Prescription Drug User Fee Act (PDUFA) action date of November 29, 2024; FDA not currently planning to hold an advisory committee meeting to discuss application

15 days ago - GlobeNewsWire

BridgeBio Pharma Shares Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Including No Mortality Reported in the Trial at 30 Months

- Phase 3 open-label, single-arm study conducted in Japan by BridgeBio licensing partner Alexion, AstraZeneca Rare Disease showed consistency with global ATTRibute-CM Phase III trial

18 days ago - GlobeNewsWire

Invitae Partners with BridgeBio Pharma to Harness Genetic Insights for the Discovery of Rare Disease Therapeutics

SAN FRANCISCO , Jan. 30, 2024 /PRNewswire/ -- Invitae  (NYSE: NVTA), a leading medical genetics company, today announced a partnership with BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage bi...

21 days ago - PRNewsWire

BridgeBio Pharma Secures up to $1.25 Billion of Capital from Blue Owl and CPP Investments to Accelerate the Development and Launch of Genetic Medicines

- The raise includes $500 million in cash from Blue Owl and CPP Investments in exchange for a 5% royalty on future global net sales of acoramidis

4 weeks ago - GlobeNewsWire

BridgeBio Pharma Announces Publication of Positive Results from Phase 3 ATTRibute-CM Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in the New England Journal of Medicine

- ATTRibute-CM demonstrated a significant treatment effect of acoramidis on the primary endpoint (a hierarchical analysis inclusive of all-cause mortality (ACM) and frequency of cardiovascular-related...

5 weeks ago - GlobeNewsWire

BridgeBio Pharma to Participate in the J.P. Morgan Healthcare Conference

PALO ALTO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and ...

6 weeks ago - GlobeNewsWire

BridgeBio announces FDA clearance of IND application for BBO-8520, a first-in-class direct inhibitor of KRASG12C (ON)

PALO ALTO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and ...

6 weeks ago - GlobeNewsWire

BridgeBio Announces First Child Dosed in PROPEL 3, its Phase 3 Clinical Trial for Infigratinib in Children with Achondroplasia

- BridgeBio has dosed the first child in PROPEL 3, a one-year, 2:1 randomized, placebo-controlled Phase 3 pivotal trial evaluating the efficacy and safety of infigratinib in children with achondroplas...

2 months ago - GlobeNewsWire

BridgeBio Pharma Announces Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

- NDA submission is based on positive results from ATTRibute-CM Phase 3 study, including a highly statistically significant result, demonstrated by a Win Ratio of 1.8 (p

2 months ago - GlobeNewsWire

BridgeBio Pharma Presents Additional Clinical Outcomes Data from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

- As previously announced, the primary endpoint (a hierarchical analysis inclusive of all-cause mortality and frequency of cardiovascular-related hospitalization) was met (Win Ratio of 1.8) with a hig...

3 months ago - GlobeNewsWire

BridgeBio Pharma to Present Additional Data from the Phase 3 ATTRibute-CM Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the American Heart Association (AHA) Scientific Sessions 2023

PALO ALTO, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and ...

3 months ago - GlobeNewsWire

BridgeBio Pharma Reports Third Quarter 2023 Financial Results and Business Update

- Presented detailed positive results from the ATTRibute-CM Phase 3 study of acoramidis at the European Society of Cardiology (ESC) Congress, demonstrating that patients survived more and were hospita...

3 months ago - GlobeNewsWire

BridgeBio Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PALO ALTO, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and ...

4 months ago - GlobeNewsWire

BridgeBio Pharma Announces New England Journal of Medicine Publication of Positive Encaleret Proof-of-Concept Phase 2b Results in Patients with Autosomal Dominant Hypocalcemia Type 1 (ADH1)

- In our study, encaleret restored physiologic mineral homeostasis in 13 participants with ADH1, specifically correcting hypocalcemia and reducing hypercalciuria

4 months ago - GlobeNewsWire

BridgeBio Pharma Shares Positive Long-Term Data from an Ongoing Phase 2 Study, which Support the Potential Use of Glycosylated Alpha-dystroglycan (⍺DG) Levels as a Surrogate Endpoint in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)

- Early assessment of increased glycosylated ⍺DG levels at 3 months predicted subsequent ambulatory improvements at 9 months, supporting the use of glycosylated ⍺DG levels as a potential surrogate end...

4 months ago - GlobeNewsWire

BridgeBio and Resilience Announce Strategic Multi-Year Partnership to Advance BBP-631, BBP-812 and Future Gene Therapy Treatments

PALO ALTO, Calif. & SAN DIEGO--(BUSINESS WIRE)-- #biomanufacturing--BridgeBio Pharma, Inc. (NASDAQ: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company focused on genetic diseases and canc...

5 months ago - Business Wire

BridgeBio's stock jumps 3.8% premarket after company announces $250 million PIPE financing led by Qatari sovereign fund

BridgeBio Pharma Inc.'s stock BBIO, +1.11% jumped 3.8% in premarket trade Monday, after the company announced a $250 million private investment in public equity, or PIPE, equity offering led by the Qa...

5 months ago - Market Watch

BridgeBio Pharma Announces $250 Million Private Placement Equity Financing

- $250 million financing led by Qatar Investment Authority (QIA) with significant participation from four of the largest investment management firms in the US

5 months ago - GlobeNewsWire

BridgeBio Pharma to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

PALO ALTO, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and...

5 months ago - GlobeNewsWire

BridgeBio Pharma Announces Positive Feedback from the U.S. FDA and EU EMA on the Regulatory Path for a Pivotal Phase 3 Trial of Infigratinib in Children with Achondroplasia

- BridgeBio completed an end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA), and a scientific advice engagement with the European Union (EU) European Medicines Agency (EMA)

5 months ago - GlobeNewsWire

BridgeBio Pharma to Present Detailed Results from the Phase 3 ATTRibute Study in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) at European Society of Cardiology (ESC) Congress 2023

PALO ALTO, Calif., Aug. 24, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and ...

6 months ago - GlobeNewsWire

BridgeBio Pharma Reports Second Quarter 2023 Financial Results and Business Update

- Announced consistently positive results from the Phase 3 ATTRibute-CM study of acoramidis in patients with transthyretin amyloid cardiomyopathy (ATTR-CM), including a highly statistically significan...

7 months ago - GlobeNewsWire